Merck Serono

Summary

Organization: Merck Serono
Country: Switzerland

Top Publications

  1. ncbi PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
    Christian Rommel
    Merck Serono International S A, 9 Chemin des Mines, 1211 Geneva, Switzerland
    Nat Rev Immunol 7:191-201. 2007
  2. doi A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin
    David W Warne
    Merck Serono International SA, Geneva, Switzerland
    Fertil Steril 92:594-604. 2009
  3. ncbi Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis
    C Pena-Rossi
    New Therapies, Merck Serono International S A, Geneva, Switzerland
    Aliment Pharmacol Ther 28:758-67. 2008
  4. pmc Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study
    Claudia Pena Rossi
    Merck Serono S A Geneva, 15bis, Chemin des Mines, CH 1211 Geneva 20, Switzerland
    BMC Gastroenterol 9:22. 2009
  5. pmc An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus
    C Pena-Rossi
    Merck Serono S A, Geneva, Switzerland
    Lupus 18:547-55. 2009
  6. doi A novel role for receptor like protein tyrosine phosphatase zeta in modulation of sensorimotor responses to noxious stimuli: evidences from knockout mice studies
    David Lafont
    Istituto di Ricerche Biomediche A Marxer, Merck Serono Ivrea Research Centre, 10010 Colleretto Giacosa TO, Italy
    Behav Brain Res 201:29-40. 2009
  7. pmc Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment
    Rita Agostinetto
    Merck Serono SpA, Guidonia Montecelio, Rome, Italy
    Reprod Biol Endocrinol 7:48. 2009
  8. ncbi Analytical identification of additional impurities in urinary-derived gonadotrophins
    R Bassett
    Merck Serono S A Geneva, 11 Chemin des Mines, Geneva 1201, Switzerland
    Reprod Biomed Online 19:300-13. 2009
  9. doi Anti-chemokine small molecule drugs: a promising future?
    Amanda E I Proudfoot
    Merck Serono Geneva Research Center, Merck Serono International SA, 9 Chemin des Mines, 1202 Geneva, Switzerland
    Expert Opin Investig Drugs 19:345-55. 2010
  10. doi Factors related to successful ovulation induction in patients with WHO group II anovulatory infertility
    C M Howles
    Merck Serono S A Geneva, Switzerland an affiliate of Merck KGaA, Darmstadt, Germany
    Reprod Biomed Online 20:182-90. 2010

Scientific Experts

Detail Information

Publications30

  1. ncbi PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
    Christian Rommel
    Merck Serono International S A, 9 Chemin des Mines, 1211 Geneva, Switzerland
    Nat Rev Immunol 7:191-201. 2007
    ....
  2. doi A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormone and human chorionic gonadotropin
    David W Warne
    Merck Serono International SA, Geneva, Switzerland
    Fertil Steril 92:594-604. 2009
    ..To compare the efficacy and safety of recombinant human FSH (r-hFSH) and hCG treatment for male hypogonadotropic hypogonadism (HH) in different populations and to identify characteristics predictive of spermatogenesis...
  3. ncbi Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis
    C Pena-Rossi
    New Therapies, Merck Serono International S A, Geneva, Switzerland
    Aliment Pharmacol Ther 28:758-67. 2008
    ..Interferon (IFN)-beta-1a has potent immunoregulatory properties, including stimulation of host defence mechanisms and thus represents a potential treatment...
  4. pmc Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study
    Claudia Pena Rossi
    Merck Serono S A Geneva, 15bis, Chemin des Mines, CH 1211 Geneva 20, Switzerland
    BMC Gastroenterol 9:22. 2009
    ..IFN beta-1a therefore offers promise as a treatment for CD...
  5. pmc An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus
    C Pena-Rossi
    Merck Serono S A, Geneva, Switzerland
    Lupus 18:547-55. 2009
    ..This supports the utility of this therapeutic approach in the treatment of autoimmune diseases, such as SLE...
  6. doi A novel role for receptor like protein tyrosine phosphatase zeta in modulation of sensorimotor responses to noxious stimuli: evidences from knockout mice studies
    David Lafont
    Istituto di Ricerche Biomediche A Marxer, Merck Serono Ivrea Research Centre, 10010 Colleretto Giacosa TO, Italy
    Behav Brain Res 201:29-40. 2009
    ..Moreover, RPTPz -/- mice displayed reduced responses to moderate thermal and tactile stimuli, both in baseline and under inflammatory conditions. These findings assign novel functional role of RPTPz in motor coordination and nociception...
  7. pmc Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment
    Rita Agostinetto
    Merck Serono SpA, Guidonia Montecelio, Rome, Italy
    Reprod Biol Endocrinol 7:48. 2009
    ..The ability to vary the FSH to LH dose ratio in a single injection without compromising the bioactivity of either gonadotrophin or generating losses of active principle is important for physicians and patients alike...
  8. ncbi Analytical identification of additional impurities in urinary-derived gonadotrophins
    R Bassett
    Merck Serono S A Geneva, 11 Chemin des Mines, Geneva 1201, Switzerland
    Reprod Biomed Online 19:300-13. 2009
    ..By using a comprehensive proteomic approach, it has been shown that the recombinant FSH preparation has greater purity than either of the urine-derived preparations...
  9. doi Anti-chemokine small molecule drugs: a promising future?
    Amanda E I Proudfoot
    Merck Serono Geneva Research Center, Merck Serono International SA, 9 Chemin des Mines, 1202 Geneva, Switzerland
    Expert Opin Investig Drugs 19:345-55. 2010
    ..Chemokines activate seven transmembrane G protein-coupled receptors, making them extremely attractive therapeutic targets for the pharmaceutical industry...
  10. doi Factors related to successful ovulation induction in patients with WHO group II anovulatory infertility
    C M Howles
    Merck Serono S A Geneva, Switzerland an affiliate of Merck KGaA, Darmstadt, Germany
    Reprod Biomed Online 20:182-90. 2010
    ....
  11. doi Discovery of a novel series of potent S1P1 agonists
    Stefano Crosignani
    Merck Serono SA, 9 Chem des Mines, 1202 Geneva, Switzerland
    Bioorg Med Chem Lett 20:1516-9. 2010
    ..The compounds were able to induce internalization of the S1P1 receptor, and a selected compound was shown to be able to induce lymphopenia in mice after oral dosing...
  12. doi Discovery of a novel series of CXCR3 antagonists
    Stefano Crosignani
    Merck Serono SA, Geneva, Switzerland
    Bioorg Med Chem Lett 20:3614-7. 2010
    ..Starting from an HTS positive, iterative optimization gave potent compounds (IC(50) 15 nM in a chemotaxis assay). The strategy employed to improve the metabolic stability of these derivatives is described...
  13. doi A high-throughput protein refolding screen in 96-well format combined with design of experiments to optimize the refolding conditions
    Vincent Dechavanne
    Geneva Research Center, Merck Serono S A, Department of Protein and Cell Sciences, 9 Chemin des Mines, 1202 Geneva, Switzerland
    Protein Expr Purif 75:192-203. 2011
    ..Thus, the method described herein is a useful tool to determine the feasibility of refolding and to identify high-yield scalable refolding conditions optimized for each individual protein...
  14. pmc In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review
    Geoffrey H Trew
    Merck Serono, Bedfont Cross, Stanwell Road, Feltham, Middlesex, TW14 8NX, UK
    Reprod Biol Endocrinol 8:137. 2010
    ....
  15. pmc Knockout mice reveal a role for protein tyrosine phosphatase H1 in cognition
    Claudia Patrignani
    MerckSerono Ivrea, Colleretto G, TO 10010, Italy
    Behav Brain Funct 4:36. 2008
    ..abstract:..
  16. doi ExactFDR: exact computation of false discovery rate estimate in case-control association studies
    Jerome Wojcik
    Department of Bioinformatics, Merck Serono Geneva Research Center, 1202 Geneva, Switzerland
    Bioinformatics 24:2407-8. 2008
    ..It provides a quick and accurate non-conservative estimator of the proportion of false positives in a given selection of markers, and is therefore an efficient and pragmatic tool for the analysis of genome-wide association studies...
  17. ncbi Identification, synthesis, and biological evaluation of novel pyrazoles as low molecular weight luteinizing hormone receptor agonists
    Catherine Jorand-Lebrun
    Merck Serono Geneva Research Center, Bat B3, 9, Chemin des Mines, 1211 Geneva, Switzerland
    Bioorg Med Chem Lett 17:2080-5. 2007
    ..31 microM) and in vivo in a model of testosterone induction in rats (significant effect at 32 mpk ip)...
  18. ncbi Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers
    Alain Munafo
    Merck Serono S A, 9 Chemin des Mines, Geneva 1202, Switzerland
    Eur J Clin Pharmacol 63:647-56. 2007
    ..This study assesses the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of atacicept...
  19. ncbi Phosphoinositide 3-kinase gamma inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment
    Chiara Ferrandi
    Molecular Medicine, Pharmacology Department, RBM Merck Serono Via Ribes 1, Colleretto Giacosa TO, Italy
    J Pharmacol Exp Ther 322:923-30. 2007
    ..Therefore, the PI3Kgamma pathway plays an important role in controlling neutrophil chemotaxis during early steps of inflammation...
  20. pmc Tocolytic effect of a selective FP receptor antagonist in rodent models reveals an innovative approach to the treatment of preterm labor
    Andre Chollet
    Merck Serono, Geneva, Switzerland
    BMC Pregnancy Childbirth 7:S16. 2007
    ..This role of FP is briefly reviewed. In this study, we tested the hypothesis that an orally active and selective FP antagonist may arrest labor and delay parturition in animal models...
  21. ncbi Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation
    Hong Ji
    Merck Serono S A, Geneva Research Center, Geneva, Switzerland
    Blood 110:2940-7. 2007
    ..Thus, the pathology in the p110gammadelta-deficient mice is likely to be secondary to a developmental block in the thymus that leads to lymphopenia-associated inflammatory responses...
  22. ncbi Biochemical characterization of USP7 reveals post-translational modification sites and structural requirements for substrate processing and subcellular localization
    Amaury Fernandez-Montalvan
    Expertise Platform Proteases, Novartis Institutes for BioMedical Research, Basel, Switzerland
    FEBS J 274:4256-70. 2007
    ....
  23. ncbi In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties
    Tiziana Adage
    Merck Serono Ivrea Research Center, RBM S p a, Colleretto Giacosa, Italy
    Eur Neuropsychopharmacol 18:200-14. 2008
    ..i.d.) was able to normalize PCP-induced hyperlocomotion. These results suggest that AS057278 has the potential to anti-psychotic action toward both cognitive and positive symptoms of schizophrenia...
  24. ncbi Beneficial effects of r-h-CLU on disease severity in different animal models of peripheral neuropathies
    G Dati
    RBM, Società soggetta all attività di direzione e coordinamento da parte della Merck Serono S A, Turin, Italy
    J Neuroimmunol 190:8-17. 2007
    ..These data demonstrate that clusterin is capable of ameliorating clinical, neurophysiological and pathological signs in models of peripheral neuropathies...
  25. pmc AS601245, a c-Jun NH2-terminal kinase (JNK) inhibitor, reduces axon/dendrite damage and cognitive deficits after global cerebral ischaemia in gerbils
    S Carboni
    Department of Pharmacology, RBM, an affiliate of Merck Serono, Colleretto Giacosa, Italy
    Br J Pharmacol 153:157-63. 2008
    ..The aim of the present study was to further investigate if AS601245 in addition to its ability to protect neurons also could protect neurites and preserve memory after cerebral ischaemia, in gerbils...
  26. pmc Dynamic simulation of regulatory networks using SQUAD
    Alessandro Di Cara
    Swiss Institute of Bioinformatics, Vital IT Group, Quartier Sorge Batiment Genopode, CH 1015 Lausanne, Switzerland
    BMC Bioinformatics 8:462. 2007
    ..In this paper we present a software implementation of such methodology...
  27. doi Characterisation of an inclusion complex between cladribine and 2-hydroxypropyl-beta-cyclodextrin
    Valeria van Axel Castelli
    Merck Serono SpA, Tiburtina Site, via L Einaudi 11, 00012 Guidonia Montecelio, Roma, Italy
    J Pharm Sci 97:3897-906. 2008
    ..This tablet formulation is currently under investigation for the treatment of patients with MS...
  28. doi Drugging the Plasmodium kinome: the benefits of academia-industry synergy
    Didier Leroy
    Merck Serono International S A, Geneva Research Center, 9, Chemin des Mines, Case postale 54, CH 1211 Genève 20, Switzerland
    Trends Pharmacol Sci 29:241-9. 2008
    ..Early characterisation of distribution, metabolism, pharmacokinetic (DMPK) and toxicology parameters are considered as well...
  29. doi The use of chemokine antagonists in EAE models
    Amanda E I Proudfoot
    Merck Serono Geneva Research Centre, 9 Chemin des Mines, Geneva, Switzerland
    J Neuroimmunol 198:27-30. 2008
    ..We will discuss these strategies and their successes and failures to prevent disease symptoms and the insights they have provided...
  30. doi In vivo processing of CXCL12α/SDF-1α after intravenous and subcutaneous administration to mice
    Bruno Antonsson
    Department of Protein and Cell Sciences, Geneva Research Center, Merck Serono S A, Geneva, Switzerland
    Proteomics 10:4342-51. 2010
    ....